With 13 years of experience and an outstanding record of performance, the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) is optimally positioned to support the HPTN in 2013 and beyond. As part of the HPTN Leadership Group, the LC will help shape the network's scientific agenda. The HPTN LC will oversee laboratory activities at study sites;perform Quality Control/Quality Assurance (QA/QC) and specialized testing for HPTN protocols;evaluate and validate assays for use in HPTN protocols;develop novel assays to achieve study objectives;and perform ancillary studies related to HIV prevention. The HPTN LC has comprehensive QA/QC, Virology, and Pharmacology Cores, with Support Laboratories in other key areas (Sexually Transmitted Diseases, Microbiology, Immunology, and Toxicology). The HPTN LC has extensive experience supporting HIV prevention trials in the United States, South America, Asia, and Africa and has led efforts to harmonize laboratory procedures across networks and in other groups. The HPTN LC has supported HPTN protocols evaluating behavioral, biomedical, and structural interventions for HIV prevention, often delivered in combination in a wide range of settings and non-traditional venues. This includes observational, Phase I, Phase II and Phase III studies, with interventions delivered to HIV uninfected individuals, HIV-infected individuals, couples, cohorts, and communities. HPTN study populations include adolescents, women, men who have sex with men, serodiscordant couples, injection drug users, and individuals with acute HIV infection, with some trials enrolling >50,000 participants.
The Specific Aims of the HPTN LC are:
Aim 1 : To provide leadership, expertise, and laboratory support to the HPTN;
Aim 2 : To support site laboratories and ensure the quality of HPTN laboratory results;
Aim 3 : To advance HIV prevention science through assay development and biomedical research. A strong and effective LC is particularly important in the HPTN because of the vast international scope, diversity, and complexity of HIV prevention trials. This award will enable the HPTN to continue its mission to identify effective strategies for HIV prevention that will help end the HIV/AIDS epidemic.

Public Health Relevance

The goal of HIV Prevention Trials Network (HPTN) is to identify effective strategies for HIV prevention. The HPTN Laboratory Center (LC) is part of the HPTN leadership group. HPTN LC investigators will oversee laboratory testing performed at study sites, analyze samples collected in HPTN studies, develop novel laboratory assays, and perform laboratory-related research relevant to HIV prevention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI068613-08
Application #
8554494
Study Section
Special Emphasis Panel (ZAI1-TS-A (S1))
Program Officer
Gilbreath, Michael J
Project Start
2006-06-01
Project End
2020-11-30
Budget Start
2014-01-01
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$3,209,530
Indirect Cost
$795,872
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Sabapathy, Kalpana; Hensen, Bernadette; Varsaneux, Olivia et al. (2018) The cascade of care following community-based detection of HIV in sub-Saharan Africa - A systematic review with 90-90-90 targets in sight. PLoS One 13:e0200737
Eisenberg, Anna L; Patel, Eshan U; Packman, Zoe R et al. (2018) Short Communication: Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV Incidence Testing. AIDS Res Hum Retroviruses 34:1013-1016
Widdice, Lea E; Hsieh, Yu-Hsiang; Silver, Barbara et al. (2018) Performance of the Atlas Genetics Rapid Test for Chlamydia trachomatis and Women's Attitudes Toward Point-Of-Care Testing. Sex Transm Dis 45:723-727
Dize, Laura; Martin, Diana; Gwyn, Sarah et al. (2018) Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease. Int J STD AIDS 29:1324-1329
Fogel, Jessica M; Sandfort, Theodorus; Zhang, Yinfeng et al. (2018) Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. AIDS Behav :
Laeyendecker, Oliver; Konikoff, Jacob; Morrison, Douglas E et al. (2018) Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. J Int AIDS Soc 21:
Margolick, Joseph B; Bream, Jay H; Nilles, Tricia L et al. (2018) Relationship Between T-Cell Responses to CMV, Markers of Inflammation, and Frailty in HIV-uninfected and HIV-infected Men in the Multicenter AIDS Cohort Study. J Infect Dis 218:249-258
Mitchell, Kate M; Dimitrov, Dobromir; Hughes, James P et al. (2018) In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS 32:809-818
Schlusser, Katherine E; Sharma, Shweta; de la Torre, Pola et al. (2018) Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. AIDS Behav 22:2277-2283
Miller, William C; Hoffman, Irving F; Hanscom, Brett S et al. (2018) A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet 392:747-759

Showing the most recent 10 out of 235 publications